Maries van den Broek

Dr. Maries van den Broek

orcid

Research Focus & Metrics

Academic Career Length

41Years (1986-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 October 2019 in European Journal of Immunology
Verified
Journal Article
Open access
ACAndrea Cossarizza
Andrea Cossarizza
HCHyun-Dong Chang
Hyun-Dong Chang
ARAndreas Radbruch
Andreas Radbruch
AAAndreas Acs
Andreas Acs
DADieter Adam
Dieter Adam
AZArturo Zychlinsky
Arturo Zychlinsky
These guidelines are a consensus work of a considerable number of members of the immunology and flow cytometry community. They provide the theory and key practical aspects of flow cytometry enabling immunologists to avoid the common errors that often undermine immunological data. Notably, there are comprehensive sections of all major immune cell types with helpful Tables detailing phenotypes in murine and human cells. The latest flow cytometry techniques and applications are also described, featuring examples of the data that can be generated and, importantly, how the data can be analysed. Furthermore, there are sections detailing tips, tricks and pitfalls to avoid, all written and peer‐reviewed by leading experts in the field, making this an essential research companion.

1 May 2017 in Cell
Verified
Journal Article
Open access
SCStéphane Chevrier
Stéphane Chevrier
JLJacob Harrison Levine
Jacob Harrison Levine
VZVito Riccardo Tomaso Zanotelli
Vito Riccardo Tomaso Zanotelli
KSKarina Silina
Karina Silina
DSDaniel Schulz
Daniel Schulz
BBBernd Bodenmiller
Bernd Bodenmiller
Immune cells in the tumor microenvironment modulate cancer progression and are attractive therapeutic targets. Macrophages and T cells are key components of the microenvironment, yet their phenotypes and relationships in this ecosystem and to clinical outcomes are ill defined. We used mass cytometry with extensive antibody panels to perform in-depth immune profiling of samples from 73 clear cell renal cell carcinoma (ccRCC) patients and five healthy controls. In 3.5 million measured cells, we identified 17 tumor-associated macrophage phenotypes, 22 T cell phenotypes, and a distinct immune composition correlated with progression-free survival, thereby presenting an in-depth human atlas of the immune tumor microenvironment in this disease. This study revealed potential biomarkers and targets for immunotherapy development and validated tools that can be used for immune profiling of other tumor types.

1 May 2019 in Cell
Verified
Journal Article
Open access
JWJohanna Wagner
Johanna Wagner
MRMaria Anna Rapsomaniki
Maria Anna Rapsomaniki
SCStéphane Chevrier
Stéphane Chevrier
TATobias Anzeneder
Tobias Anzeneder
CLClaus Langwieder
Claus Langwieder
BBBernd Bodenmiller
Bernd Bodenmiller
Breast cancer is a heterogeneous disease. Tumor cells and associated healthy cells form ecosystems that determine disease progression and response to therapy. To characterize features of breast cancer ecosystems and their associations with clinical data, we analyzed 144 human breast tumor and 50 non-tumor tissue samples using mass cytometry. The expression of 73 proteins in 26 million cells was evaluated using tumor and immune cell-centric antibody panels. Tumors displayed individuality in tumor cell composition, including phenotypic abnormalities and phenotype dominance. Relationship analyses between tumor and immune cells revealed characteristics of ecosystems related to immunosuppression and poor prognosis. High frequencies of PD-L1+ tumor-associated macrophages and exhausted T cells were found in high-grade ER+ and ER- tumors. This large-scale, single-cell atlas deepens our understanding of breast tumor ecosystems and suggests that ecosystem-based patient classification will facilitate identification of individuals for precision medicine approaches targeting the tumor and its immunoenvironment.

3 February 2013 in Nature
Verified
Journal Article
Closed access
PDF file
HBHeidi Braumüller
Heidi Braumüller
TWThomas Wieder
Thomas Wieder
EBEllen Brenner
Ellen Brenner
SASonja Aßmann
Sonja Aßmann
MHMatthias Hahn
Matthias Hahn
MRMartin Röcken
Martin Röcken

30 January 2005 in Nature Immunology
Verified
Journal Article
Closed access
PDF file
HPHans Christian Probst
Hans Christian Probst
KMKathy McCoy
Kathy McCoy
TOTaku Okazaki
Taku Okazaki
THTasuku Honjo
Tasuku Honjo
MBMaries van den Broek
Maries van den Broek

28 February 2018 in Cancer Research
Verified
Journal Article
Closed access
PDF file
KSKarīna Siliņa
Karīna Siliņa
ASAlex Soltermann
Alex Soltermann
FAFarkhondeh Movahedian Attar
Farkhondeh Movahedian Attar
RCRuben Casanova
Ruben Casanova
Zina Maria UckeleyZina Maria Uckeley
Zina Maria Uckeley
MBMaries van den Broek
Maries van den Broek
In solid tumors, the presence of lymph node–like structures called tertiary lymphoid structures (TLS) is associated with improved patient survival. However, little is known about how TLS develop in cancer, how their function affects survival, and whether they are affected by cancer therapy. In this study, we used multispectral microscopy, quantitative pathology, and gene expression profiling to analyze TLS formation in human lung squamous cell carcinoma (LSCC) and in an experimental model of lung TLS induction. We identified a niche of CXCL13+ perivascular and CXCL12+LTB+ and PD-L1+ epithelial cells supporting TLS formation. We also characterized sequential stages of TLS maturation in LSCC culminating in the formation of germinal centers (GC). In untreated patients, TLS density was the strongest independent prognostic marker. Furthermore, TLS density correlated with GC formation and expression of adaptive immune response–related genes. In patients treated with neoadjuvant chemotherapy, TLS density was similar, but GC formation was impaired and the prognostic value of TLS density was lost. Corticosteroids are coadministered with chemotherapy to manage side effects in LSCC patients, so we evaluated whether they impaired TLS development independently of chemotherapy. TLS density and GC formation were each reduced in chemotherapy-naïve LSCC patients treated with corticosteroids before surgery, compared with untreated patients, a finding that we confirmed in the experimental model of lung TLS induction. Overall, our results highlight the importance of GC formation in TLS during tumor development and treatment. Significance: Corticosteroid treatment during chemotherapy negatively affects the development of tertiary lymphoid structures and abrogates their prognostic value in patients with lung cancer. Cancer Res; 78(5); 1308–20. ©2018 AACR.